Many advances in treatment rely on new formulations of know drugs. As with most drugs, pharmaceutical companies consider patent-based recoupment of development and regulatory costs required to bring new formulations to market an essential prerequisite to pursuing a new formulation. Without effective patent protection, many new formulations would not be developed. A new decision from the Federal Circuit (the nation’s main patent court) has applied the lowered standard for obviousness of inventions to invalidate the patent to a new formulation of a known drug.
Click the link below to read the full alert.